Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest TB Stories

2012-08-22 06:24:25

Phase I study in Lenexa, KS, of novel vaccine targeting TB virulence and latency ROCKVILLE, Md. and SEATTLE, Aug. 22, 2012 /PRNewswire-USNewswire/ -- Aeras and the Infectious Disease Research Institute (IDRI) announce today the start of the first clinical trial of IDRI's novel tuberculosis vaccine candidate, ID93 + GLA-SE. The Phase I clinical trial will assess the safety, tolerability and immunogenicity of the vaccine candidate in 60 healthy adult volunteers. The study will be...

2012-08-13 12:57:53

Scientists of the Antwerp Institute of Tropical Medicine have breathed new life into a forgotten technique and so succeeded in detecting resistant tuberculosis in circumstances where so far this was hardly feasible. Tuberculosis bacilli that have become resistant against our major antibiotics are a serious threat to world health. If we do not take efficient and fast action, 'multiresistant tuberculosis' may become a worldwide epidemic, wiping out all medical achievements of the last...

2012-07-24 06:27:07

ATLANTA, July 24, 2012 /PRNewswire-USNewswire/ -- New collaborative studies being presented by the Centers for Disease Control and Prevention (CDC) at the XIX International AIDS Conference confirm early treatment of HIV patients results in better outcomes, suggest use of viral load testing to detect treatment failure, and highlight factors associated with low rate of ART enrollment. CDC plays an essential role in implementing the U.S. President's Emergency Plan for AIDS Relief (PEPFAR)...

2012-07-24 11:05:59

Lancet paper finds novel drug regimen could be more effective than existing treatments; TB Alliance's trial to test drugs in combination saves years in research time A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two weeks and could be more effective than existing treatments, according to a study published today in the...

2012-07-24 10:10:48

In January, 2012, the U.S. Food and Drug Administration (FDA) issued new guidelines on dosing of an HIV medication used to treat people infected with both HIV and tuberculosis (TB) because of a potential interaction between two of the main drugs used to treat each disease. The drug rifampin, used for treating TB, can lower levels of the HIV medicine efavirenz, so the FDA recommended that patients who weigh more than 50 kg (110 pounds) and who are taking both medications should get 30...

2012-07-02 02:23:38

RARITAN, N.J., July 2, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the use of the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults. If approved by the FDA, bedaquiline would be the first drug with a new...

2012-06-28 20:18:49

Inhibiting immune response early on could speed treatment time, prevent relapse Inhibiting a key immune response in mice during initial multi-drug treatment for tuberculosis could – paradoxically – shorten treatment time for the highly contagious lung infection according to new research from Johns Hopkins Children's Center and the Center for TB Research. Shorter duration of drug therapy is key, researchers say, to increase treatment compliance for the growing global health...

Swab Technique Spots Tuberculosis In Non-human Primates
2012-06-25 10:16:35

TB infections, a serious threat to monkeys and apes, previously had been difficult to detect Tuberculosis can be a serious threat to monkeys and apes. A new technique for detecting the tuberculosis-causing bacteria could help in protecting the health of primate populations. The method can spot TB even among infected primates that show no outward sign of disease, but are still capable of spreading infection to others of their kind. Existing tests for TB in primates are difficult to...

2012-06-17 23:01:34

Immune Network Ltd. (IMMFF), announces the completion of a Phase II trial of a once-daily M. vaccae pill (V7) conducted by Immunitor in Ukraine. The imm02 study was aimed to seek whether oral formulation of inactivated whole cell mycobacteria can shorten TB treatment duration. Vancouver, Canada (PRWEB) June 17, 2012 The phase II, placebo-controlled trial, conducted by experts in the field of TB immunotherapy, was set to evaluate the efficacy of tableted, heat-killed Mycobacterium vaccae in...

2012-06-12 02:26:25

SAN FRANCISCO, June 12, 2012 /PRNewswire/ -- Medizone International, Inc. (The Company) (MZEI:OB) (MZEI:QB) announced today that in achieving 100% kill rates with TB in three successive trials, it had achieved another important milestone in its understanding of the antimicrobial limits of its recently launched disinfection technology, AsepticSure(TM). Dr. Michael E Shannon, President of Medizone International, stated, "With one third of the world's population currently infected with...